TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20134096
Drug: Shock wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shock wave (SW) therapy
Study: 18391039
Drug: Entecavir 1
Normalized name: entecavir 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 1 mg daily dose in HIV- and HBV-coinfected patients
Study: 18391039
Drug: Entecavir 1
Normalized name: entecavir 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entecavir 1 mg daily dose in HBV-monoinfected patients
Study: 18391039
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of entecavir pharmacokinetics between HIV- and HBV-coinfected and HBV-monoinfected patients
Study: 12520628
Drug: Norethindrone acetate/ethinyl
Normalized name: norethindrone acetate/ethinyl estradiol 1 mg-5 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone acetate/ethinyl estradiol tablets administered with a high-fat meal
Study: 12520628
Drug: Norethindrone acetate/ethinyl
Normalized name: norethindrone acetate/ethinyl estradiol 1 mg-5 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone acetate/ethinyl estradiol tablets administered fasting
Study: 12520628
Drug: Norethindrone acetate/ethinyl
Normalized name: norethindrone acetate/ethinyl estradiol 1 mg-5 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethindrone acetate/ethinyl estradiol tablets administered in solution
Study: 9433680
Drug: Vitamins (beta‐carotene,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins (beta‐carotene, 6 mg; vitamin C, 120 mg; and vitamin E, 15 mg)
Study: 9433680
Drug: Trace elements
Normalized name: trace elements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trace elements (zinc, 20 mg and selenium, 100 micrograms)
Study: 8270292
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg on alternate days
Study: 8270292
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg (single dose)
Study: 3304837
Drug: Ranitidine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 200 mg/day iv
Study: 3304837
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg/day iv
Study: 24682207
Drug: Caffeine (2.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (2.9 mg/kg, equivalent to 200 mg or 2 espressos for a 70-kg adult)
Study: 18177726
Drug: Taranabant (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taranabant (0.5, 2, 4, and 6 mg once per day)
Study: 16188812
Drug: Surfactant (Curosurf)
Normalized name: Curosurf
DrugBank: Poractant alfa (DB09113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Surfactant (Curosurf) at 200 mg/kg, repeated doses of 200, 100, and 100 mg/kg at 6-12 h intervals, maximum of four doses if OI deteriorated by >2 from baseline
Study: 8888089
Drug: Adalat CC
Normalized name: Adalat CC
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adalat CC
Study: 27487342
Drug: PTH‐1‐37 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH‐1‐37 (10 µg, 20 µg, 40 µg)
Study: 27487342
Drug: PTH‐1‐34 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH‐1‐34 (20 µg)
Study: 1725153
Drug: 400mg aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg aqueous solution
Study: 1725153
Drug: 400mg tablet
Normalized name: IBU 400mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400mg tablet
Study: 1725153
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 200mg tablets
Study: 6178151
Drug: Hapten (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hapten (10 or 20 ml) before dextran infusion
Study: 30885996
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg
Study: 30885996
Drug: Imatinib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 800 mg
Study: 31813633
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid 10 mg
Study: 25418218
Drug: Human recombinant
Normalized name: Human recombinant AP
DrugBank: Recombinant human alkaline phosphatase (DB17672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human recombinant BNP (rhBNP; 0.005 μg/kg/min)
Study: 25418218
Drug: Isotonic normal
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic normal saline (NaCl 0.9%, 1 mL/kg/h) for 24 hours before CA or PCI
Study: 20635771
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT) for Panic Disorder
Study: 18192953
Drug: Natriuretic peptides
Normalized name: Natriuretic peptides b
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natriuretic peptides (NPs) applied prophylactically, in lower doses, for prolonged duration.
Study: 2913779
Drug: Prazosin, Propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin, Propranolol, Hydrochlorothiazide (all drug treatment groups)
Study: 22334770
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatment groups
Study: 64267
Drug: gestonorone caproate
Normalized name: Gestonorone caproate
DrugBank: Gestonorone caproate (DB14677)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gestonorone caproate (200 mg daily and 200 mg on alternate days)
Study: 64267
Drug: cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyproterone acetate (300 mg daily)
Study: 31952493
Drug: Active TDM
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TDM (therapeutic drug monitoring) of beta-lactam and fluoroquinolones
Study: 26350273
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg once daily for 12 days
Study: 26350273
Drug: Placebo once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily for 12 days
Study: 10708180
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL of sterile water)
Study: 30012385
Drug: Flavonols (63.36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavonols (63.36 mg/d)
Study: 30012385
Drug: Flavanols (107.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanols (107.61 mg/d)
Study: 30012385
Drug: Flavanones (40.92
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavanones (40.92 mg/d)
Study: 30012385
Drug: Catechins (63.36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catechins (63.36 mg/d)
Study: 26970526
Drug: Tofacitinib XR
Normalized name: tofacitinib Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib XR 11 mg QD
Study: 26970526
Drug: Tofacitinib IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib IR 5 mg twice daily
Study: 26970526
Drug: Tofacitinib XR
Normalized name: tofacitinib Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib XR 11 mg QD (fed state)
Study: 26970526
Drug: Tofacitinib XR
Normalized name: tofacitinib Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib XR 11 mg QD (multiple doses)
Study: 26970526
Drug: Tofacitinib IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib IR 5 mg twice daily (multiple doses)
Study: 21935685
Drug: Intravenous dezocine
Normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous dezocine 0.1 mg/kg
Study: 20194448
Drug: Rituximab retreatment
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab retreatment (2 x 1000 mg IV)
Study: 12740233
Drug: Hydrocortisone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone (200 to 300 mg/d) for 1 to 3 weeks
Study: 1624634
Drug: h-EGF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: h-EGF (10 micrograms/mL, applied topically twice a day for up to 10 weeks)
Study: 1624634
Drug: Placebo (applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (applied topically twice a day for up to 10 weeks)
Study: 6334524
Drug: 1,25-dihydroxyvitamin D
Normalized name: 1,25-dihydroxyvitamin D
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,25-dihydroxyvitamin D (mean dose 0.4 micrograms/day)
Study: 29372470
Drug: Topiroxostat (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat (40 to 160 mg/day, administered BID for 28 weeks)
Study: 29372470
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo administered BID for 28 weeks)
Study: 27863179
Drug: Bedaquiline (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedaquiline (24 weeks treatment)
Study: 25358679
Drug: Antenatal milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal milk expressing starting at 36 weeks gestation, encouraged to express twice daily for 10 min.
Study: 19227901
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 mg/day for 3 months
Study: 19227901
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no inhibitors of GMG-CoA-reductase)
Study: 15895898
Drug: SINGLE therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SINGLE therapy (initially sulfasalazine with or without prednisolone)
Study: 15895898
Drug: COMBI therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMBI therapy (sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone)
Study: 15895898
Drug: sIL‐2R <442
Approvals — FDA: no, EMA: no, PMDA: no
Description: sIL‐2R <442 U/ml
Study: 2105673
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg naltrexone
Study: 2205128
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg naltrexone
Study: 23727387
Drug: Apomorphine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine (1.5 mg)
Study: 21820539
Drug: Weekly musculoskeletal
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly musculoskeletal treatment for 6 weeks in addition to normal optimal physiotherapy care
Study: 11573528
Drug: Ketoprofen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 0.5 mg kg(‐1) at induction followed by continuous infusion of 3 mg kg(‐1) over 24 h (pre ketoprofen group)
Study: 11573528
Drug: Ketoprofen 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 0.5 mg kg(‐1) after surgery followed by continuous infusion of 3 mg kg(‐1) over 24 h (post ketoprofen group)
Study: 9661740
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of carbamazepine (CBZ)
Study: 9661740
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day of valproic acid (VPA)
Study: 9661740
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of carbamazepine (CBZ) and 800 mg/day of valproic acid (VPA)
Study: 8151854
Drug: Steam treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steam treatment (40 L/min of heated saturated air at 43 degrees C for 60 minutes)
Study: 8151854
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (2 L/min of ambient air at 20 degrees C to 24 degrees C)
Study: 3219316
Drug: 0.3 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 g/kg body-weight per day
Study: 3219316
Drug: 0.45 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 g/kg body-weight per day
Study: 3219316
Drug: 0.6 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 g/kg body-weight per day
Study: 3219316
Drug: 0.75 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g/kg body-weight per day
Study: 28840615
Drug: Phospholipidated Curcumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phospholipidated Curcumin (1 g/day, containing 200 mg of pure curcumin)
Study: 28840615
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 g/day)
Study: 26057939
Drug: Aspirin supplementation
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin supplementation (acute and chronic)
Study: 23937271
Drug: Dapoxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine 30 mg plus mirodenafil 50 mg (group B)
Study: 23937271
Drug: Dapoxetine 30
Normalized name: duloxetine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapoxetine 30 mg plus placebo (group A)
Study: 21803422
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg linagliptin after an overnight fast of at least 10 hours
Study: 21803422
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg linagliptin after ingestion of a high-fat, high-calorie breakfast
Study: 19781210
Drug: Atorvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (20 mg/qn)
Study: 12932070
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no atorvastatin)
Study: 24625934
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 100 mg
Study: 9576201
Drug: alpha2b-IFN (Intron-A)
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha2b-IFN (Intron-A) maintenance therapy
Study: 9576201
Drug: no maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: no maintenance therapy
Study: 7936018
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of azathioprine
Study: 2953770
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (1.25 mg/kg body weight over 3 hours)
Study: 20932130
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser therapy (2,940 nm, 60 mJ/pulse, 2 Hz, 20 s)
Study: 20932130
Drug: Nd:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nd:YAG laser therapy (1,064 nm, 100 mJ/pulse, 15 Hz, 100 s)
Study: 20932130
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser therapy (808 nm, 100 mW, 20s)
Study: 18823688
Drug: Daily hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily hemodialysis (DHD)
Study: 12271300
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied 3 times per week for 8 weeks
Study: 12271300
Drug: Vehicle cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle cream applied to the other side of the body
Study: 9649912
Drug: Enalapril 10-40
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10-40 mg o.d. after 3 and 12 months
Study: 7530029
Drug: bovine heparin
Normalized name: BOVINE HEPARIN
DrugBank: Heparin, bovine (DB15404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bovine heparin 300 u. kg‐1 (standard)
Study: 7530029
Drug: heparin 300
Normalized name: TAUROLIDINE 40.5 mg in 3 mL / HEPARIN 3000 [USP'U] in 3 mL INTRALUMINAL SOLUTION [DEFENCATH]
Approvals — FDA: no, EMA: no, PMDA: no
Description: heparin 300 u. kg‐1 followed by a continuous infusion of 10,000 u. kg‐1 until the end of CPB
Study: 7530029
Drug: heparin 600
Normalized name: Heparine
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: heparin 600 u. kg‐1
Study: 7530029
Drug: heparin 600
Normalized name: Heparine
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: heparin 600 u. kg‐1 in addition to high‐dose aprotinin 2 million iu before CPB, 500,000 iu h‐1 until the end of operation and 2 million iu added to the prime
Study: 1952132
Drug: saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline solution (control)
Study: 1632701
Drug: Oral OK-432
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral OK-432
Study: 2586435
Drug: Intravenous OK-432
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous OK-432
Study: 781905
Drug: Busulphan (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulphan (mean dosage of 464 mg over 301 days)
Study: 31752850
Drug: Pitavastatin 1
Normalized name: PITAVASTATIN 1MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 1 mg
Study: 23556337
Drug: Non-G carriers
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-G carriers of ABCB1 G2677T/A
Study: 21813728
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy cessation for 1 month or 2 months before the next screening mammogram
Study: 21813728
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of hormone therapy
Study: 16444660
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg dose of Melissa officinalis and Valeriana officinalis
Study: 16444660
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg dose of Melissa officinalis and Valeriana officinalis
Study: 16444660
Drug: 600 mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg, 1200 mg, and 1800 mg doses of Melissa officinalis and Valeriana officinalis
Study: 16444660
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg and 1200 mg doses of Melissa officinalis and Valeriana officinalis
Study: 14992980
Drug: Galantamine (8,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (8, 16, or 24 mg/day)
Study: 11789969
Drug: Cilostazol 50
Normalized name: cilostazol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 50 mg bid
Study: 24630869
Drug: Vi-rEPA conjugate
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi-rEPA conjugate vaccine
Study: 16490583
Drug: Oral clindamycin
Normalized name: clindamycin Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral clindamycin 300 mg BID
Study: 16490583
Drug: Oral amoxicillin/clavulanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin/clavulanic acid 1 g BID
Study: 10623706
Drug: Temozolomide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (200 mg/m²/d for 5 days every 28 days)
Study: 10623706
Drug: Dacarbazine (DTIC)
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dacarbazine (DTIC) (250 mg/m²/d for 5 days every 21 days)
Study: 8250314
Drug: Flumazenil 10
Normalized name: flumazenil 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil 10 mg
Study: 30972696
Drug: Ticagrelor (0.125-2.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (0.125-2.25 mg/kg)
Study: 25233931
Drug: Nicotine metabolism
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine metabolism by cytochrome P450 2A6‐catalyzed C‐oxidation
Study: 19668021
Drug: 17 alpha‐hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha‐hydroxyprogesterone caproate (17P) 250 mg weekly injections
Study: 10440559
Drug: Baseline comparisons
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline comparisons across treatment groups.
Study: 1983724
Drug: Alprazolam, 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam, 1.5 mg/day
Study: 400194
Drug: Total Body
Normalized name: Total Body Massager Item
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Body Irradiation (TBI) and Chemotherapy (CVP)
Study: 400194
Drug: Chemotherapy (CVP)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CVP)
Study: 400194
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TBI and CVP
Study: 28124802
Drug: Frequent consumption
Normalized name: ALLERGENIC EXTRACT,PENICILLIUM FREQUENTANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent consumption of Caspian white fish marinated in essential oil of Perilla frutescens (EOPF), 434 g each week or four meals per week.
Study: 28124802
Drug: Frequent consumption
Normalized name: ALLERGENIC EXTRACT,PENICILLIUM FREQUENTANS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequent consumption of Caspian white fish without EOPF, 434 g each week or four meals per week.
Study: 15247553
Drug: Efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 600 mg once daily
Study: 17065182
Drug: Intensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intervention at a heart failure clinic by a clinician and a cardiovascular nurse, including 9 scheduled patient contacts over 1 year, comprehensive education, treatment optimisation, and self-care advice.
Study: 8245671
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g and tinidatsole 500 mg
Study: 8245671
Drug: Aminoglycoside (netilmycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycoside (netilmycin 150 mg or tobramycin 80 mg) with tinidatsole
Study: 19210135
Drug: NER uncoated
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NER uncoated 2 x 500 mg
Study: 19210135
Drug: NER coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: NER coated 1 x 1000 mg
Study: 19210135
Drug: NER coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: NER coated 2 x 500 mg
Study: 19210135
Drug: NER uncoated
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NER uncoated 1 x 1000 mg
Study: 29794285
Drug: Control (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (usual treatment)
Study: 15548759
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (alpha‐tocopherol 100 mg/day, beta‐carotene 6 mg/day, vitamin C 100 mg/day, selenium 50 microg/day)